Ayalew Tefferi

ORCID: 0000-0003-4605-3821 · 3 papers in corpus
article 2008
Risk factors for leukemic transformation in patients with primary myelofibrosis
·doi:10.1002/cncr.23505

BACKGROUND: Previous prognostic studies in primary myelofibrosis have focused on risk factors for overall survival and have resulted in the establishment of several prognostic scoring systems. However, to the authors' knowledge, information…

article 2007
Erythropoietin Therapy Does Not Benefit Transfusion-Dependent Primary Myelofibrosis Patients and Treatment Response Is Infrequent with a Baseline Hemoglobin Level ≥ 10 g/dL.
·doi:10.1182/blood.v110.11.3555.3555

Abstract BACKGROUND: The potential risks of tumor growth promotion and thromboembolism associated with erythropoietin (Epo) therapy warrant cautious use of erythropoiesis stimulating agents (ESA). Recent data suggest a surprising and signif…

article 2002
Splenectomy for immune thrombocytopenic purpura: long-term results and treatment of postsplenectomy relapses
Annals of Hematology ·doi:10.1007/s00277-002-0461-8

Information regarding prognostic determinants of outcome after splenectomy for adult immune thrombocytopenic purpura (ITP) and the management of postsplenectomy relapse is limited. Among 140 adult patients with ITP who had therapeutic splen…